611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

NurseWise 24-Hour Crisis Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Health Sciences
Basic InformationLatest News
Blood Test May Gauge Death Risk After Surgery150-Year-Old Drug May Shorten 'Off' Time for Parkinson's PatientsBrain May Be Organized by Functions, Not Body PartsBody Temperature Might Give Clues to ComaCould Young Blood Boost the Aging Brain?A 'Brainwave' to Help Fight PTSDDizziness in Parkinson's May Be Due to Cerebral HypoperfusionMisunderstood Gene Tests May Lead to Unnecessary MastectomiesScientists Extend Lives of Mice With ALSFDA Approves 1st Direct-to-Consumer Genetic Risk TestsFDA OKs 1st At-Home Genetic Tests for 10 Disorders'SuperAgers' Have Less Whole-Brain Cortical Volume LossHigh Thyroid Hormone Levels Tied to Stiffer ArteriesBrain Changes May Mark Risk of Financial Exploitation in SeniorsRegular Exercise Slows Decline Even in Advanced Parkinson's DzBrain-Computer Link Restores Some Movement to Quadraplegic ManScientists Spot Gene for Rare Disorder Causing Deafness, BlindnessNew Technology Makes Gene Mapping Cheaper, Faster: StudyTurning Back the Aging Clock -- in MiceNew Parkinson's Drug Xadago ApprovedBrain 'Rewires' to Work Around Early-Life BlindnessBrain Training for Cancer Survivors' Nerve DamageASA: Vagus Nerve Stimulation May Enhance Stroke RecoveryGene Therapy: A Breakthrough for Sickle Cell Anemia?Gene Therapy Shows Promise for Aggressive LymphomaThe Brain Can Produce Its Own Sugar: ReportCould Parkinson's Disease Raise Stroke Risk?NHL Veterans Pledge Their Brains to ResearchMRIs Can Be Safe for People With Heart Devices …Scientists Shed Light on Possible Cause of NearsightednessBrain Chip Helps Paralyzed 'Type' With Their MindDoes Mercury in Fish Play a Role in ALS?Repeat Head Hits May Not Put NFL Players at Risk of Motor ProblemsMRI Can Identify Early Signs of ASD in High-Risk InfantsEvidence of CTE Identified in Former Soccer PlayersSpace Reshapes Astronauts' Brains: StudyDiagnostic Potential for Blood-Based NfL in Parkinson's DiseaseIs It Parkinson's or Something Else? Blood Test Might Tell30 Former NFL Players Pledge Their Brains for ResearchAstronaut Twins Give Clues to Health Hazards of SpaceflightBrain-Computer Interface Lets Locked-In Patients CommunicateGene Discoveries Offer New Height InsightsBrain Scans Let 'Locked-In' ALS Patients CommunicateCaffeine Found to Reduce Age-Related InflammationfMRI May Be Better Way to Map Brain Prior to Epilepsy SurgeryVagus Nerve Might Play a Role in Fighting Inflammatory DiseaseBlood Levels of Meat-Linked Chemical Tied to Odds of Heart TroubleGSK3 Antagonists Promote Natural Tooth Repair in MiceScans Hint at Running's Brain Benefits, Even When YoungStudy Links Stuttering to Less Blood Flow in Brain
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

Gene Therapy Shows Promise for Aggressive Lymphoma

HealthDay News
by -- Margaret Farley Steele
Updated: Feb 28th 2017

new article illustration

TUESDAY, Feb. 28, 2017 (HealthDay News) -- An experimental gene therapy for aggressive non-Hodgkin lymphoma beat back more than a third of cancers that seemed untreatable, the therapy's developers report.

Thirty-six percent of over 100 very ill lymphoma patients appeared disease-free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif.

These patients had not responded to usual treatments and had no other options, Kite said Tuesday in a news release.

Overall, more than four out of five patients with the blood cancer saw their cancer reduced by more than half for at least part of the study, the company said.

"This seems extraordinary ... extremely encouraging," one cancer specialist, Dr. Roy Herbst, told the Associated Press.

But Herbst, who is chief of medical oncology at Yale Cancer Center in New Haven, Conn., said longer follow-up is needed to see if the benefit continues.

Still, he said, "This certainly is something I would want to have available." Side effects, which had been a concern, seemed manageable in this study, he said.

The therapy -- called CAR-T cell therapy -- enables the patient's own blood cells to kill the cancer cells.

Lymphoma is a general term for cancers that begin in the lymph system. The lymph system is part of the immune system, which helps the body fight disease.

Here's how the treatment works: A patient's blood is filtered so immune cells called T-cells can be altered to contain a cancer-fighting gene. The cells are returned to the patient intravenously, and the cancer-targeting cells then multiply in the patient's body.

The U.S. National Cancer Institute developed the gene approach and licensed it to Kite. Now, Kite and another pharmaceutical giant, Novartis AG, are competing to gain approval of the treatment, according to the AP.

Kite reportedly intends to seek U.S. Food and Drug Administration approval this spring and approval in Europe later this year. It could be the first gene therapy approved in the United States, the news report noted.

Although the therapy appears to benefit a significant number of patients, it is not risk-free. Researchers believe two patients died of treatment-related causes, the AP reported.

Other side effects included anemia or other blood problems that were treated, and neurological problems such as sleepiness, confusion, tremor or difficulty speaking, which typically lasted only a few days, the wire service reported.

Overall, however, the therapy seems safe, according to Dr. Steven Rosenberg, chief of surgery branch at the National Cancer Institute. He was not involved with the study.

"It's a safe treatment, certainly a lot safer than having progressive lymphoma," Rosenberg told the AP. He said he has a patient who was treated this way who is still in remission seven years later.

The cost of such treatment hasn't been reported yet, but immune system therapies tend to be very expensive.

The results are scheduled for presentation at the American Association for Cancer Research conference in April. Until published in a peer-reviewed medical journal, the data and conclusions should be considered preliminary.

More information

The U.S. National Cancer Institute has more about lymphoma.